AADI Penghasilan resik perusahaan Aadi Bio

Aadi Bioscience minimizes capital expenditures by outsourcing production and testing to third-party contractors. The company's net income demonstrates financial stability, with this metric equaling -0.06. Profit dynamics are driven by the market launch of Fyarro for the treatment of rare neoplasms and expansion into the hospital sector of targeted oncology therapy through the scaling of clinical trials.

AADI aadibio.com: Penghasilan resik ing interval 04.07.2022 - 19.03.2025

Rincian metrik komprehensif lan analitis aadibio.com (AADI)

- rega saham lan konsensus proyeksi valuasi:

Bagan rega Aadi Bioscience, Inc.|AADI - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar AADI|AADI - Nilai Perusahaan

- data ekuitas miturut neraca:

Nilai Buku Siji Saham Aadi Bioscience|AADI - Aset Bersih Perusahaan|Koefisien Nilai Pasar marang Nilai Buku aadibio.com|AADI - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Aadi Bioscience|AADI - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Aadi Bioscience, Inc.|AADI - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku AADI|AADI - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Aadi Bioscience|Likuiditas kritis aadibio.com

- data bathi bisnis lan rasio investasi:

AADI - Bathi resik

Pambiji fundamental:Aadi Bioscience

Analyzing the business model's resilience to external shocks requires an assessment of the daily cash balance after deducting all operating expenses and taxes. The strong reputation of Fyarro therapy within the oncology community creates a foundation of stability, which, through the organization's net income, allows investors to differentiate the actual solvency of Aadi Bioscience (AADI) from speculative expectations regarding the results of future clinical trials.

Pesaing utama